Innate Pharma Statistics

Total Valuation

Innate Pharma has a market cap or net worth of EUR 110.53 million. The enterprise value is 98.79 million.

Market Cap	110.53M
Enterprise Value	98.79M

Important Dates

The next confirmed earnings date is Thursday, September 17, 2026.

Earnings Date	Sep 17, 2026
Ex-Dividend Date	n/a

Share Statistics

Innate Pharma has 93.83 million shares outstanding. The number of shares has increased by 10.54% in one year.

Current Share Class	93.83M
Shares Outstanding	93.83M
Shares Change (YoY)	+10.54%
Shares Change (QoQ)	+6.11%
Owned by Insiders (%)	0.74%
Owned by Institutions (%)	1.61%
Float	65.94M

Valuation Ratios

PE Ratio	n/a
Forward PE	1.24
PS Ratio	12.27
PB Ratio	-5.09
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.01
EV / Sales	10.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-1.87

Financial Position

The company has a current ratio of 1.27

Current Ratio	1.27
Quick Ratio	1.14
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-0.43
Interest Coverage	-122.75

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-38.85%
Return on Invested Capital (ROIC)	-165.88%
Return on Capital Employed (ROCE)	-207.17%
Weighted Average Cost of Capital (WACC)	7.19%
Revenue Per Employee	55,245
Profits Per Employee	-301,699
Employee Count	174
Asset Turnover	0.10
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -34.24% in the last 52 weeks. The beta is 0.74, so Innate Pharma's price volatility has been lower than the market average.

Beta (5Y)	0.74
52-Week Price Change	-34.24%
50-Day Moving Average	1.28
200-Day Moving Average	1.59
Relative Strength Index (RSI)	44.14
Average Volume (20 Days)	417,086

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Innate Pharma had revenue of EUR 9.01 million and -49.18 million in losses. Loss per share was -0.55.

Revenue	9.01M
Gross Profit	-34.62M
Operating Income	-54.01M
Pretax Income	-49.18M
Net Income	-49.18M
EBITDA	-53.31M
EBIT	-54.01M
Loss Per Share	-0.55

Full Income Statement

Balance Sheet

The company has 34.31 million in cash and 22.57 million in debt, giving a net cash position of 11.74 million or 0.13 per share.

Cash & Cash Equivalents	34.31M
Total Debt	22.57M
Net Cash	11.74M
Net Cash Per Share	0.13
Equity (Book Value)	-21.70M
Book Value Per Share	-0.23
Working Capital	10.06M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -52.76 million and capital expenditures -140,000, giving a free cash flow of -52.90 million.

Operating Cash Flow	-52.76M
Capital Expenditures	-140,000
Depreciation & Amortization	700,000
Net Borrowing	-8.91M
Free Cash Flow	-52.90M
FCF Per Share	-0.56

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-599.77%
Pretax Margin	-546.11%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Innate Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.54%
Shareholder Yield	-10.54%
Earnings Yield	-44.49%
FCF Yield	-47.86%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Innate Pharma has an Altman Z-Score of -11.09 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-11.09
Piotroski F-Score	2